Ascendis Pharma A/S (ASND) vs Charles River Laboratories International, Inc. (CRL)

A side-by-side comparison of Ascendis Pharma A/S and Charles River Laboratories International, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ASND vs CRL

growth of $100 · dividends reinvested · last 10y
ASND +1027.2% (+27.4%/yr)CRL +274.1% (+14.1%/yr)ASND compounded faster over this window
05001kStart $10020182020202220242026$1,127$374
ASND CRL

ASND vs CRL: by the numbers

  • •CRL is the larger company ($14.97B vs $14.16B market cap).
  • •ASND is profitable (71.08% net margin) while CRL runs a net loss (-5.96%).
  • •ASND grew revenue faster over the past five years (189.92% vs 4.08% CAGR).

Metrics side by side

Valuation

MetricASNDCRL
P/E ratio17.33N/A
Forward P/EN/A27.39
P/S ratio11.593.74
P/B ratio8.645.27
EV / EBITDA93.7922.49
FCF yield2.73%2.48%

Profitability

MetricASNDCRL
Gross margin90.18%32.24%
Operating margin-18.92%12.35%
Net margin71.08%-5.96%
ROE52.97%-8.40%
ROIC5.85%7.72%

Growth (annualized)

MetricASNDCRL
Revenue CAGR (5Y)189.92%4.08%
FCF CAGR (5Y)N/A6.43%
Total return CAGR (5Y)7.40%-4.99%

Frequently asked

Which has grown faster, ASND or CRL?
Over the past five years, ASND grew revenue faster — ASND at a 189.92% CAGR versus CRL at 4.08%.
Is ASND or CRL more profitable?
ASND runs the higher net margin — ASND at 71.08% versus CRL at -5.96%.
How have ASND and CRL total returns compared?
Over the past 10 years, ASND delivered 27.41% and CRL delivered 14.12% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.